Trials / Completed
CompletedNCT01894373
Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis
Autologous Cytokine Induced Killer Cells as Adjuvant Adoptive Immunotherapy in Patients With Psoriasis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 12 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
to determine the therapeutic roles of CIK cells on patients with psoriasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adoptive Immunotherapy | Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells |
| BIOLOGICAL | CIK |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2013-07-10
- Last updated
- 2018-05-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01894373. Inclusion in this directory is not an endorsement.